Suven Life Sciences Limited

This study tested a new drug called ropanicant in 41 adults with moderate to severe major depressive disorder. The main goal was to check safety and side effects, while also measuring how well it improved depression symptoms using a standard rating scale. The trial was open-label…

This completed Phase 2b trial tested whether ropanicant, an experimental drug taken twice daily, can reduce symptoms of major depressive disorder. 214 adults with moderate to severe depression received either ropanicant or a placebo for 6 weeks. The main goal was to see if the dr…

This early-stage trial tested the safety and tolerability of a new drug called SUVN-I6107 in 64 healthy adults. Participants received either the drug or a placebo tablet, and researchers monitored for side effects and how the drug moves through the body. The study also looked at …